Share on StockTwits

Incyte (NASDAQ:INCY) is set to issue its Q214 quarterly earnings data on Thursday, July 31st. Analysts expect the company to announce earnings of $0.05 per share and revenue of $140.72 million for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

Incyte (NASDAQ:INCY) last issued its quarterly earnings data on Thursday, May 1st. The company reported ($0.21) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.17) by $0.04. The company had revenue of $89.80 million for the quarter, compared to the consensus estimate of $97.70 million. During the same quarter last year, the company posted ($0.12) earnings per share. Incyte’s revenue was up 26.3% compared to the same quarter last year. On average, analysts expect Incyte to post $-0.41 EPS for the current fiscal year and $0.25 EPS for the next fiscal year.

Shares of Incyte (NASDAQ:INCY) opened at 48.84 on Wednesday. Incyte has a 52-week low of $23.15 and a 52-week high of $70.86. The stock has a 50-day moving average of $52.35 and a 200-day moving average of $55.67. The company’s market cap is $8.187 billion.

A number of research firms have recently commented on INCY. Analysts at Nomura reiterated a “buy” rating on shares of Incyte in a research note on Thursday, July 24th. They now have a $90.00 price target on the stock. On the ratings front, analysts at Zacks reiterated a “neutral” rating on shares of Incyte in a research note on Friday, July 4th. They now have a $58.00 price target on the stock. Two analysts have rated the stock with a sell rating, one has issued a hold rating and twelve have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $62.80.

In other Incyte news, EVP James M. Daly sold 11,111 shares of the stock on the open market in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $48.54, for a total transaction of $539,327.94. The transaction was disclosed in a filing with the SEC, which is available at this link.

Incyte Corporation (NASDAQ:INCY) is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat serious unmet medical needs.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.